

## 38<sup>th</sup> Annual Meeting Program Schedule

Schedule is current as of Oct. 16. Visit [www.sitcancer.org/2023](http://www.sitcancer.org/2023) for the most up-to-date schedule.

Friday, Nov. 3, 2023

### Session 100: Presidential Welcome

**Time:** 7:45–7:50 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

7:45 a.m. **Presidential Welcome**

Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

### Session 101: Awards Ceremony

**Time:** 7:50–8:20 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

7:50 a.m. **Introduction**

Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

7:55 a.m. **2023 SITC Fellows of the Academy of Immuno-Oncology Recognition**

**2023 Lifetime Achievement Award**

**2023 Tara Withington Public Service Award**

**2023 Pedro J. Romero Service to JITC Award**

**2023 Steven A. Rosenberg Scholar Award**

### Session 102: Richard V. Smalley Memorial Award and Lectureship

**Time:** 8:20–9:10 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

8:20 a.m. **Introduction**

Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

8:25 a.m. **Richard V. Smalley Award Presentation: Cancer Immunoediting: Targets, Mechanisms and Implications for Immunotherapy**

Robert D. Schreiber, PhD, FAIO – *Washington University School of Medicine*

9:10 a.m. **Break**

### Session 103: Leveraging Tumor-rejecting Leukocytes to Cure Tumors by Immunotherapy

**Time:** 9:25–11:30 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Co-Chairs:** Carla Rothlin, PhD – *Yale School of Medicine*

Sjoerd H. van der Burg, PhD – *Leiden University Medical Center*

9:25 a.m. **Introduction**

Carla Rothlin, PhD – *Yale School of Medicine*

9:30 a.m. **Interplay Between T Cells and Macrophages/Neutrophils in Therapeutic Vaccination**

Sjoerd H. van der Burg, PhD – *Leiden University Medical Center*

## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

- 9:55 a.m. **Neutrophil-Activating Therapy for the Treatment of Cancer**  
Ian Linde, PhD – *Fred Hutchinson Cancer Center*
- 10:20 a.m. **Eosinophils in the Anti-Cancer Response**  
Marleen Kok, MD, PhD – *Netherlands Cancer Institute*
- 10:45 a.m. **(989) Cancer sculpts granulopoiesis to generate tumor-supportive neutrophils**  
Daniela C. Cerezo-Wallis, PhD – *Yale University*
- 11 a.m. **(1101) Activation of myeloid cells suppresses metastatic ovarian cancer via tumoricidal neutrophils and IL-27-secreting macrophages**  
Taito Miyamoto, MD, PhD – *The Wistar Institute*
- 11:15 a.m. **(878) T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants**  
Daniel Hirschhorn, PhD – *Weill Cornell Medical College*

### Session 104: Late-Breaking Abstract Session

- Time:** 11:30 a.m.–12 p.m. PDT
- Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)
- Chair:** Mary Kate Kasler, DNP – *Memorial Sloan Kettering Cancer Center*
- 11:30 a.m. **(1510) Multiomic functional biomarkers for cancer prediction and early detection**  
Marine Fidelle, PharmD, PhD – *Gustave Roussy*
- 11:45 a.m. **(1514) In vivo CAR-M: redirecting endogenous myeloid cells with mRNA for cancer immunotherapy**  
Bindu Varghese, PhD – *Carisma Therapeutics*

### Lunch & Poster Viewing

- Time:** 12–1:30 p.m. PDT
- Location:** Ground Level - Exhibit Hall B - San Diego Convention Center

### Concurrent Session 105a: Rapid Oral Abstracts – Basic Science

- Time:** 12:15–1:15 p.m. PDT
- Location:** Ground Level - Exhibit Hall D - San Diego Convention Center
- Co-Chairs:** Geoffrey J. Markowitz, PhD – *Weill Cornell Medicine*  
Abigail E. Overacre-Delgoffe, PhD – *University of Pittsburgh*
- 12:15 p.m. **(1427) Evaluating MHC-II antigen presentation in vivo to identify targets for immunotherapy**  
Alex Jaeger, PhD – *Moffitt Cancer Center*
- 12:23 p.m. **(915) Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance**  
Nathan Reticker-Flynn, PhD – *Stanford University*
- 12:31 p.m. **(275) Inosine endows CAR T cells with features of increased stemness and anti-tumor potency**  
Dorota Klysz, PhD – *Stanford University School of Medicine*
- 12:39 p.m. **Q&A**
- 12:45 p.m. **(949) Flexible control of T cell memory and self-renewal by a reversible epigenetic switch**  
Hao Yuan Kueh – *University of Washington*

## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

- 12:53 p.m. **(386) Sheltering telomeres from oxidative damage in therapeutic T cells protects against tumor-induced immune dysfunction**  
Dayana Rivadeneira – *University of Pittsburgh*
- 1:01 p.m. **(931) Augmenting antigen presentation to improve CD8+ and CD4+ T cell responses in lung cancer**  
Sean-Luc Shanahan, BS – *Massachusetts Institute of Technology*
- 1:09 p.m. **Q&A**

### Concurrent Session 105b: Rapid Oral Abstracts – Clinical

- Time:* 12:15–1:15 p.m. PDT  
*Location:* Ground Level - Exhibit Hall C - San Diego Convention Center  
*Co-Chairs:* Abdul Rafeh Naquash, MD – *Stephenson Cancer Center Oklahoma University*  
Tanya Keenan, MD, MPH – *BCD Merck*
- 12:15 p.m. **(807) A vaccine targeting the recurrent driver mutation H3K27M induces mutation specific T- and B- cell responses in patients with diffuse midline gliomas**  
Tamara Boschert – *German Cancer Research Center (DKFZ), Heidelberg University, Helmholtz Institute for Translational Oncology (HI-TRON), MCTN Heidelberg University*
- 12:23 p.m. **(104) A spatial pharmacology approach to decipher drug-target-microenvironment interactions in situ**  
Guolan Lu, PhD – *Stanford University*
- 12:31 p.m. **(581) Final analysis of 2-THE-TOP: A phase 2 study of TTFIELDS (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma**  
Dongjiang Chen – *University of Southern California*
- 12:39 p.m. **Q&A**
- 12:45 p.m. **(1216) Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers**  
Sri Krishna, PhD – *National Cancer Institute*
- 12:53 p.m. **(229) Large-scale omics profiling reveals Type-2 functionality sustaining 8-year leukemia remission following CAR T cell therapy**  
Zhilang Bai, PhD – *Yale University*
- 1:01 p.m. **(636) BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials**  
Diane Simeone, MD – *NYU Langone Health*
- 1:09 p.m. **Q&A**

### Session 105c: Virtual Only Session: Meet an IO Expert

- Time:* 12:30–1 p.m. PDT  
*Location:* Virtual Meeting Platform  
*Co-Chair:* Crystal Mackall, MD – *Stanford University*
- 12:30 p.m. **Discussion and Q&A**  
Crystal Mackall, MD – *Stanford University*

## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

### Concurrent Session 106a: Mechanisms of Resistance to Immune Checkpoint Inhibitors

<b>Time:</b>	1:30–3:10 p.m. PDT
<b>Location:</b>	Ground Level - Exhibit Hall C - San Diego Convention Center
<b>Co-Chairs:</b>	Harriet Kluger, MD – <i>Yale University</i> Arlene Sharpe, MD, PhD, FAIO – <i>Harvard Medical School</i>
1:30 p.m.	<b>Introduction</b> Harriet Kluger, MD – <i>Yale University</i> Arlene Sharpe, MD, PhD, FAIO – <i>Harvard Medical School</i>
1:40 p.m.	<b>Non-T Cell Based Resistance Mechanisms</b> Lili Yang, PhD – <i>University of California, Los Angeles</i>
2 p.m.	<b>Immune Cell Screens</b> Hongbo Chi, PhD – <i>St. Jude Children's Research Hospital</i>
2:20 p.m.	<b>Machine Learning, Computational Biology to Study Resistance</b> David Liu, MD, MPH, MS – <i>Dana-Farber Cancer Institute</i>
2:40 p.m.	<b>(1502) Tumor heterogeneity impedes immunotherapy through driving spatially organized pockets of immunosuppression</b> Melissa Q. Reeves, PhD – <i>University of Utah Huntsman Cancer Institute</i>
2:55 p.m.	<b>(568) Tumor-intrinsic Sox2 signaling induces regulatory T cell-mediated CD8 T cell exclusion, promoting resistance to checkpoint blockade therapy in lung cancer</b> Elen Torres, PhD – <i>Koch Institute for Integrative Cancer Research at MIT</i>

### Concurrent Session 106b: Microbiome and Cancer

<b>Time:</b>	1:30–3:10 p.m. PDT
<b>Location:</b>	Upper Level - Ballroom 6CD - San Diego Convention Center
<b>Co-Chairs:</b>	Melody Smith, MD, MS – <i>Stanford University School of Medicine</i> Jennifer Wargo, MD, MMSc – <i>The University of Texas MD Anderson Cancer Center</i>
1:30 p.m.	<b>Introduction</b> Melody Smith, MD, MS – <i>Stanford University School of Medicine</i>
1:35 p.m.	<b>(1330) Gut microbiome dysbiosis promotes immune suppression and lung cancer development</b> Zahraa Rahal, MD – <i>The University of Texas MD Anderson Cancer Center</i>
1:45 p.m.	<b>Harnessing Human Gut-Derived Bacteroides to Drive Systemic Anti-Tumor Immunity</b> Rabi Upadhyay, MD – <i>New York University School of Medicine</i>
2 p.m.	<b>(1328) The use of fecal filtrate transplant to enhance response to immune checkpoint blockade</b> Golnaz Morad, DDS, PhD – <i>The University of Texas MD Anderson Cancer Center</i>
2:10 p.m.	<b>Intratumoral Microbes: From Microniches to Single Cells</b> Susan Bullman, PhD – <i>Fred Hutchinson Cancer Center</i>
2:25 p.m.	<b>(1207) A new oral microbial metabolite prodrug preserves CD8+ T cell stemness and improves the antitumor efficacy of immune checkpoint blockers</b> Youngseok Cho, PharmD, PhD – <i>University of Michigan</i>
2:35 p.m.	<b>Cell Therapy, Antibiotics, Interventional Trials</b> Marco Ruella, MD – <i>University of Pennsylvania</i>
2:50 p.m.	<b>Panel Discussion</b>



## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

### Concurrent Session 106c: Immunoprevention of Cancer

**Time:** 1:30–3:10 p.m. PDT

**Location:** Ground Level - Exhibit Hall D - San Diego Convention Center

**Co-Chairs:** Philip Castle, PhD, MPH – *National Cancer Institute*  
Catherine Wu, MD – *Dana-Farber Cancer Institute*

1:30 p.m. **Introduction**

Philip Castle, PhD, MPH – *National Cancer Institute*  
Catherine Wu, MD – *Dana-Farber Cancer Institute*

1:35 p.m. **Vaccination to Prevent/Intercept Cancer in High Risk Population**

Eduardo Vilar-Sanchez, MD, PhD – *The University of Texas MD Anderson Cancer Center*

1:55 p.m. **Immunobiology of Immunosurveillance and Prevention**

Olivera Finn, PhD, FAIO – *University of Pittsburgh*

2:15 p.m. **Novel Technologies for Cancer Immunoprevention**

Steven Reed, PhD – *HDT Bio*

2:35 p.m. **(1032) Early remodelling of CD4 T cell differentiation in lung squamous carcinogenesis**

James L. Reading, PhD – *Cancer Research UK Lung Cancer Centre of Excellence*

2:40 p.m. **(138) Shared frameshift neoantigens are expressed throughout mismatch repair deficient cancer development and are recognized by tissue infiltrating T cells that are dysregulated in advanced lesions**

Matthew Brown, MS, BA – *Icahn School of Medicine at Mount Sinai*

2:45 p.m. **Q&A, Panel Discussion**

### Concurrent Session 106d: Transforming Therapies with Project Optimus: A conversation with the FDA around how to apply and integrate project Optimus into novel clinical trials

**Time:** 1:30–3:10 p.m. PDT

**Location:** Upper Level - Ballroom 6AB - San Diego Convention Center

**Co-Chairs:** Mirat Shah, MD – *US Food and Drug Administration*  
Cecilia Yeung, MD – *Fred Hutchinson Cancer Center*

1:30 p.m. **Introduction: Setting the Stage on Project Optimus**

Cecilia Yeung, MD – *Fred Hutchinson Cancer Center*

1:40 p.m. **Panel Discussion**

Topic 1: Project Optimus in current practice: Trial design, endpoints, dosing, randomization

Topic 2: Applying Optimus to novel immunotherapy trials: Cellular therapies, vaccines, oncolytic viruses, etc.

Topic 3: Future solutions for assisting researchers in optimization: Adjusting to dynamic landscapes for ongoing trials, and implications for the future

Peter Bross, MD – *US Food and Drug Administration*

Jennifer Brudno, MD – *National Cancer Institute*

Alessandra Cesano, MD, PhD – *ESSA Pharmaceuticals*

Jane Healy, MD, PhD – *Merck*

Jason Luke, MD, FACP – *University of Pittsburgh Medical Center*

Megan Othus, PhD – *Fred Hutchinson Cancer Center*

Xiaofei (Sophie) Wang, PhD – *US Food and Drug Administration*

Cecilia Yeung – *Fred Hutchinson Cancer Center*

3:10 p.m. **Break**

# 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

## Concurrent Session 107a: Cytokines in Cancer

<b>Time:</b>	3:30–5:10 p.m. PDT
<b>Location:</b>	Ground Level - Exhibit Hall C - San Diego Convention Center
<b>Co-Chairs:</b>	Warren Leonard, MD – <i>National Institutes of Health</i> Ann Silk, MD, MS – <i>Dana-Farber Cancer Institute</i>
3:30 p.m.	<b>Introduction</b> Warren Leonard, MD – <i>National Institutes of Health</i>
3:35 p.m.	<b>PD-1 and IL-2; T Cell Exhaustion</b> Rafi Ahmed, PhD, FAIO – <i>Emory University</i>
3:55 p.m.	<b>Cytokine Engineering</b> Jamie Spangler, PhD – <i>Johns Hopkins University</i>
4:15 p.m.	<b>Clinical Perspective on the N803 Agent</b> Karim Chamie, MD – <i>University of California, Los Angeles</i>
4:35 p.m.	<b>(550) Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response</b> Eran Ophir, PhD – <i>Compugen Ltd.</i>
4:50 p.m.	<b>(1070) “Decoy-resistant” IL-18 in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma</b> David A. Schoenfeld, MD, PhD – <i>Yale Cancer Center</i>
5:05 p.m.	<b>Summary/Wrap Up</b>

## Concurrent Session 107b: Promising Novel Biotechnologies for the Next Wave of IO Innovation

<b>Time:</b>	3:30–5:10 p.m. PDT
<b>Location:</b>	Ground Level - Exhibit Hall D - San Diego Convention Center
<b>Co-Chairs:</b>	Jane Grogan, PhD – <i>Biogen</i> Zhen Su, MD, MBA – <i>Marengo Therapeutics</i>
3:30 p.m.	<b>Overview of IO Biotech</b> Zhen Su, MD, MBA – <i>Marengo Therapeutics</i>
3:40 p.m.	<b>CAR T in Solid Tumor</b> Carl June, MD, FAIO – <i>University of Pennsylvania</i>
3:55 p.m.	<b>Emerging New Modalities (Vaccines, Bi-specifics)</b> Julie Brahmer, MD – <i>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</i>
4:10 p.m.	<b>Advances in T-Cell Engagers Against Solid Tumors</b> Carolyn Britten, MD, FRCPC – <i>Amgen</i>
4:20 p.m.	<b>(599) Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/ BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors</b> Kai He, MD, PhD – <i>James Cancer Center, The Ohio State University</i>
4:30 p.m.	<b>(777) Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS)</b> Michael R. Migden, MD – <i>The University of Texas MD Anderson Cancer Center</i>

## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

4:40 p.m. **Panel: Hot topics; Future directions; Reflections**  
 Julie Brahmer, MD – *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*  
 Jane Grogan, PhD – *Biogen*  
 William Grossman, MD – *Gilead Sciences*  
 Brad Loncar, BBA – *Biotech TV*

### Concurrent Session 107c: Big Data and Data Sharing Committee

**Time:** 3:30–5:10 p.m. PDT

**Location:** Upper Level - Ballroom 6AB - San Diego Convention Center

**Co-Chairs:** Alan Hutson, PhD – *Roswell Park Comprehensive Cancer Center*  
 Lillian Kuo, PhD – *National Cancer Institute*  
 Kellie Smith, PhD – *Johns Hopkins University*

3:30 p.m. **Introduction**  
 Alan Hutson, PhD – *Roswell Park Comprehensive Cancer Center*

3:40 p.m. **NIH/NCI Data Sharing Policy, Resources and FAIR principles**  
 Jill Barnholtz-Sloan, PhD – *National Cancer Institute*

3:55 p.m. **Regulatory Obstacles around Sharing Human Subjects Data**  
 Aaron Mann – *Clinical Research Data Sharing Alliance*

4:10 p.m. **Data Sharing as a Driver of Collaboration, Data Utilization and Authorship**  
 Alessandra Cesano, MD, PhD – *ESSA Pharmaceuticals*

4:25 p.m. **Data Sharing Challenges**  
 Riyue Bao, PhD – *UPMC Hillman Cancer Center*

4:40 p.m. **Panel Discussion**

### Concurrent Session 107d: Oral Abstract Session

**Time:** 3:30–5:10 p.m. PDT

**Location:** Upper Level - Ballroom 6CD - San Diego Convention Center

**Co-Chairs:** Jeffrey Ishizuka, MD, DPhil – *Yale University*  
 Rachel Sanborn, MD – *Earle A. Chiles Research Institute*

3:30 p.m. **Introduction**

3:34 p.m. **(277) SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma**  
 Senthilnath Lakshmanachetty, PhD – *University of California, San Francisco*

3:50 p.m. **(1444) Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade**  
 Svena Verma – *Weill Cornell Medicine*

4:06 p.m. **(1416) Common metabolic adaptations empower CD8 T cell tissue residency and antitumor immunity**  
 Miguel Reina Campos, PhD – *University of California, San Diego*

4:22 p.m. **(884) Tumor-directed immunoradiotherapy enhances surveillance from the sentinel lymph node**  
 Robert Saddawi-Konefka, MD, PhD – *University of California, San Diego*

4:38 p.m. **(944) Obese, not starving: mitochondrial citrate export drives lipid accumulation and dysfunction in exhausted T cells**  
 Kellie Spahr, BSc – *University of Pittsburgh*

## 38<sup>th</sup> Annual Meeting Program Schedule

Friday, Nov. 3, 2023

4:54 p.m. **(463) Targeting a novel myeloid checkpoint Siglec-15 in GBM generates an extremely durable response with Zika virus oncolytic therapy**  
Ashwani Kesarwani, PhD – *Washington University in St. Louis*

### Concurrent Session 107e: Convergence Towards Enhanced Immunotherapy *Organized in Collaboration with Stand Up To Cancer (SU2C)*

**Time:** 3:30–5:10 p.m. PDT

**Location:** Upper Level - Meeting Room 11 - San Diego Convention Center

**Co-Chairs:** Julian Adams, PhD – *Stand Up To Cancer*  
James Gulley, MD, PhD, FACP – *National Cancer Institute*

3:30 p.m. **Introduction**  
Julian Adams, PhD – *Stand Up To Cancer*

3:40 p.m. **Driving CAR T Cells**  
Marcela Maus, MD, PhD – *Massachusetts General Hospital*

4:10 p.m. **CAR T for T Cell Lymphoma**  
Maksim Mamonkin, PhD – *Baylor College of Medicine*

4:40 p.m. **Early Detection of Lung Cancer**  
Avrum Spira, PhD – *Boston University Medical Center*

### Poster Reception

**Time:** 5:10–6:40 p.m. PDT

**Location:** Ground Level - Exhibit Hall B - San Diego Convention Center

## 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

### Session 200: Business Meeting

**Time:** 7:15–7:45 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Mary Dean, JD, CAE – *Society for Immunotherapy of Cancer*

7:15 a.m. **Introduction**

Mary Dean, JD, CAE – *Society for Immunotherapy of Cancer*

7:20 a.m. **Panel**

Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

Marco Ruella, MD – *University of Pennsylvania*

Zhen Su, MD, MBA – *Marengo Therapeutics*

### Session 201: Organizer Welcome

**Time:** 8–8:05 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Yvonne Chen, PhD – *University of California, Los Angeles*

8 a.m. **Organizer Welcome**

Yvonne Chen, PhD – *University of California, Los Angeles*

### Session 202: Keynote Address

**Time:** 8:05–8:55 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

8:05 a.m. **Introduction**

Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*

8:10 a.m. **Stressing Out the Immune System in Cancer**

Susan Kaech, PhD – *Salk Institute*

### Session 203: Stromal Cells and TLS

**Time:** 8:55–10:55 a.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)

**Chair:** Nikhil Joshi, PhD – *Yale School of Medicine*

Ellen Puré, PhD – *Perelman School of Medicine at the University of Pennsylvania*

8:55 a.m. **Introduction**

Nikhil Joshi, PhD – *Yale School of Medicine*

9:05 a.m. **TLS in Humans**

Catherine Sautes-Fridman, PhD – *Universite Paris-Cite*

9:30 a.m. **Immune Regulation by Stromal Cells**

Rolf Brekken, PhD – *University of Texas Southwestern Medical Center*

# 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

- 9:55 a.m. **A Vascular Perspective on TLS: how to make endothelial cells high**  
Gabriele Bergers, PhD – *VIB-KU Leuven, Belgium*
- 10:20 a.m. **(606) IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy**  
Minu K. Srivastava, PhD – *Genentech*
- 10:35 a.m. **(62) Pathological, transcriptomic and prognostic assessment of lymphoid aggregates in patients with primary and metastatic melanoma**  
Lilit Karapetyan, MD – *Moffitt Cancer Center*

## Session 204: Late-Breaking Abstract Session

- Time:** 11:25–11:55 a.m. PDT
- Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)
- Chair:** Alfred L. Garfall, MD – *Perelman School of Medicine at the University of Pennsylvania*
- 11:25 a.m. **(1526) Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial**  
Morena D'Alise, PhD – *Nouscom srl*
- 11:40 a.m. **(1534) Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial**  
Sapna Patel, MD – *The University of Texas MD Anderson Cancer Center*

## Lunch & Poster Viewing

- Time:** 11:55 a.m.–1:25 p.m. PDT
- Location:** Ground Level - Exhibit Hall B - San Diego Convention Center

## Concurrent Session 205a: Rapid Oral Abstracts – Basic Science

- Time:** 12:10–1:10 p.m. PDT
- Location:** Ground Level - Exhibit Hall D - San Diego Convention Center
- Co-Chairs:** Zachary A. Cooper, PhD – *AstraZeneca*  
Golnaz Morad, DDS, PhD – *The University of Texas MD Anderson Cancer Center*
- 12:10 p.m. **(409) Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics**  
Sean Arlauckas, PhD – *Beigene Biopharma*
- 12:18 p.m. **(457) Targeting FASN sensitizes irradiated glioblastoma to immune checkpoint blockade**  
Mara De Martino – *Weill Cornell Medicine*
- 12:26 p.m. **(545) Targeting autotaxin enhances immune checkpoint blockade response in NSCLC**  
Jessica Konen, PhD – *Emory University*
- 12:34 p.m. **Q&A**
- 12:40 p.m. **(872) Combined multi-omics analysis delineates the impact of epigenetic therapies on the immunopeptidome of acute myeloid leukemia**  
Jens Bauer – *University of Tübingen and University Hospital Tübingen*
- 12:48 p.m. **(144) Novel public and tumor-wide neoantigens arising from clonal aberrant splicing events drive tumor-specific T-cell responses across diverse cancer types**  
Darwin Kwok, MS – *University of California, San Francisco*

## 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

12:56 p.m. **(1015) Tissue-specific transcriptional networks identify Hic1 as a critical regulator of intestinal Trm differentiation**  
Maximilian Heeg, MD – *University of California, San Diego*

1:04 p.m. **Q&A**

### Concurrent Session 205b: Rapid Oral Abstracts – Clinical

**Time:** 12:10–1:10 p.m. PDT

**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center

**Co-Chairs:** Allison Betof Warner, MD, PhD – *Stanford Cancer Center*  
Praveen K. Bomareddy, MS, PhD, Bpharm – *Replimune Inc.*

12:10 p.m. **(1226) Surgery is a window of opportunity: biomaterial-assisted delivery of immunotherapy reduces local recurrence of soft tissue sarcoma**  
Ben Wylie, PhD – *Telethon Kids Institute*

12:18 p.m. **(218) Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient pan-cancer cohort**  
Joao Alessi, MD – *Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute*

12:26 p.m. **(923) Characterization and clinical significance of the intra and inter-tumor spatial immune heterogeneity using 3-dimensional multiplexed phenotyping in non-small cell lung cancer**  
Miguel Lopez de Rodas, MD – *Yale School of Medicine*

12:34 p.m. **Q&A**

12:40 p.m. **(1358) Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors**  
Xin Kai, PhD – *Hopewell Therapeutics Inc.*

12:48 p.m. **(53) Inducing immune response with FLASH and conventional radiation in Diffuse Midline Glioma (DMG)**  
Hanna Minns – *Oregon Health and Science University*

12:56 p.m. **(569) Dissecting resistance to immune checkpoint blockade in bladder cancer: single cell analyses link pro-inflammatory macrophages and IL-6 to CD8+ T cell suppression**  
Michelle Tran – *Icahn School of Medicine at Mount Sinai*

1:04 p.m. **Q&A**

### Session 205c: Virtual Only Session: Expert Panel Discussion

**Time:** 12:30–1 p.m. PDT

**Location:** Virtual Meeting Platform

**Co-Chairs:** Judith Agudo, PhD – *Dana-Farber Cancer Institute*  
Michael Davies, MD, PhD – *The University of Texas MD Anderson Cancer Center*

12:30 p.m. **Panel Discussion**  
Judith Agudo, PhD – *Dana-Farber Cancer Institute*  
Michael Davies, MD, PhD – *The University of Texas MD Anderson Cancer Center*

## 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

### Session 206: Presidential Session

<b>Time:</b>	1:25–2:50 p.m. PDT
<b>Location:</b>	Ground Level - Exhibit Hall C - San Diego Convention Center (Overflow Viewing in Exhibit Hall D)
<b>Chair:</b>	Leisha A. Emens, MD, PhD – <i>Ankyra Therapeutics</i>
1:25 p.m.	<b>Introduction</b> Leisha Emens, MD, PhD – <i>Ankyra Therapeutics</i>
1:30 p.m.	<b>(1006) High doses of MHC-II neoantigens in peptide cancer vaccines induce tumor-specific inhibitory cytolytic CD4+ T cells</b> Hussein Sultan, PhD – <i>Washington University, School of Medicine</i>
1:45 p.m.	<b>(1399) Identification of alternative splicing-derived targets for TCR-T cell therapies</b> Elise Wilcox, PhD – <i>Fred Hutchinson Cancer Center</i>
2 p.m.	<b>Expert Discussant</b> Carl June, MD, FAIO – <i>University of Pennsylvania</i>
2:10 p.m.	<b>(916) Making their own off switch: Fgl2 produced by antigen-specific CD8 T cells tempers the CD8 T-cell response via apoptosis of FcγRIIBpos CD8 T cell</b> Kelsey Bennion, BS – <i>Emory University</i>
2:25 p.m.	<b>(1111) Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC</b> Carlos Wagner Wanderley, PhD – <i>Brigham and Women's Hospital</i>
2:40 p.m.	<b>Expert Discussant</b> Lorenzo Galluzzi, PhD – <i>Weill Cornell Medicine</i>
2:50 p.m.	<b>Break</b>

### Concurrent Session 207a: Immune Therapy Toxicities, Evolving Frontiers

<b>Time:</b>	3:20–4:45 p.m. PDT
<b>Location:</b>	Ground Level - Exhibit Hall C - San Diego Convention Center
<b>Co-Chairs:</b>	Douglas Johnson, MD, MSCI – <i>Vanderbilt University Medical Center</i> Bianca Santomaso, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i>
3:20 p.m.	<b>Introduction</b> Douglas Johnson, MD, MSCI – <i>Vanderbilt University Medical Center</i> Bianca Santomaso, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i>
3:35 p.m.	<b>CAR</b> Nirali Shah, MD – <i>National Institutes of Health</i>
3:55 p.m.	<b>irAE</b> Alexandra-Chloé Villani, PhD – <i>Massachusetts General Hospital</i>
4:15 p.m.	<b>(1254) Tumor-mediated education of bone marrow neutrophil progenitors facilitates the development of checkpoint inhibitor-associated toxicity</b> Brent A. Hanks, MD, PhD – <i>Duke University</i>
4:30 p.m.	<b>(1244) Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors</b> Stephanie Gu – <i>Memorial Sloan Kettering Cancer Center</i>



## 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

### Concurrent Session 207b: Metabolism and the Immune Response to Cancer

- Time:** 3:20–4:45 p.m. PDT  
**Location:** Ground Level - Exhibit Hall D - San Diego Convention Center  
**Co-Chairs:** Ping-Chih Ho, PhD – *Ludwig Cancer Center*  
 Robert Leone, MD – *Johns Hopkins Hospital*
- 3:20 p.m. **Introduction**  
 Ping Chih Ho, PhD – *University of Lausanne & University Hospital of Lausanne*
- 3:30 p.m. **Aging and Diet**  
 Lydia Lynch, PhD – *Brigham and Women's Hospital*
- 3:50 p.m. **Pyruvate Utilization**  
 Marcia Haigis, PhD – *Harvard Medical School*
- 4:10 p.m. **Lipids Regulate CD8+ T Cell Metabolic Fitness and Antitumor Immunity**  
 Teresa Manzo, PhD – *European Institute of Oncology*
- 4:30 p.m. **(933) Heme-mediated reprogramming guides CD8+ T cell exhaustion in response to mitochondrial dysfunction**  
 Yingxi Xu, PhD – *University of Lausanne*

### Concurrent Session 207c: Neoadjuvant Therapy: Lessons Learned and Future Directions

- Time:** 3:20–4:45 p.m. PDT  
**Location:** Upper Level - Ballroom 6AB - San Diego Convention Center  
**Co-Chairs:** Sangeetha Prabhakaran, MD, FACS – *University of New Mexico*  
 Vernon Sondak, MD – *H. Lee Moffitt Cancer Center & Research Institute*
- 3:20 p.m. **Introduction**  
 Sangeetha Prabhakaran, MD, FACS – *University of New Mexico*
- 3:25 p.m. **Principles Learned from Neoadjuvant Therapy for Cutaneous Malignancies**  
 Sapna Patel, MD – *The University of Texas MD Anderson Cancer Center*
- 3:40 p.m. **Patient Selections for NAI, Defining Who Needs Adjuvant Immunotherapy, Difference Between Academic vs. Community-Based Biomarkers for Immunotherapy Response**  
 Roberto Salgado, MD, PhD – *GZA-ZNA Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia*
- 3:55 p.m. **Principles Learned from Neoadjuvant Therapy for Lung/Colon Cancers**  
 Janis Taube, MD, MSc – *Johns Hopkins School of Medicine*
- 4:10 p.m. **NAI and Surgical Considerations, Specific Toxicities Influencing Surgery, Changing Surgical Management Based on Toxicities**  
 Stephanie Downs-Canner, MD – *Memorial Sloan Kettering Cancer Center*
- 4:25 p.m. **(1361) Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer**  
 Bridget P. Keenan, MD, PhD – *University of California, San Francisco*
- 4:35 p.m. **Panel Discussion**

# 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

## Concurrent Session 207d: Oral Abstract Session

Time:	3:20–4:45 p.m. PDT
Location:	Upper Level - Ballroom 6CD - San Diego Convention Center
Co-Chairs:	Charu Aggarwal, MD, MPH – <i>University of Pennsylvania School of Medicine</i> Laura Rogers, PhD – <i>Mayo Clinic</i>
3:20 p.m.	<b>Introduction</b>
3:25 p.m.	<b>(377) IL-15 treatment enhances the in vivo anti-tumor efficacy of sipuleucel-T by activating CD8+ T and NKT effector cells, augmenting tumor infiltration, and reversing immunoresistance pathways</b> Russell Pachynski, MD – <i>Washington University School of Medicine</i>
3:41 p.m.	<b>(578) Anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans</b> Kelly Burke, MD, PhD – <i>Dana-Farber Cancer Institute, Harvard Medical School</i>
3:57 p.m.	<b>(596) AMBER, Part 2B: a Phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy</b> Diwakar Davar, MD – <i>UPMC Hillman Cancer Center</i>
4:13 p.m.	<b>(608) Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors</b> Christopher Chen, MD – <i>Stanford University School of Medicine</i>
4:29 p.m.	<b>(690) High safety and efficacy of CRISPR-Based non-viral PD1 locus specific integrated anti-CD19 CAR-T Cells (BRL-201) in treating relapsed or refractory non-hodgkin's lymphoma: First-in-human phase I study</b> Biao Zheng, MD, PhD – <i>BRL Medicine Inc.</i>
4:45 p.m.	<b>Break</b>

## Concurrent Session 208a: Neuroimmunology in Cancer

Time:	5:05–6:30 p.m. PDT
Location:	Ground Level - Exhibit Hall C - San Diego Convention Center
Co-Chairs:	Robert Prins, PhD – <i>University of California, Los Angeles</i> Sebastien Talbot, PhD – <i>Queen's University</i>
5:05 p.m.	<b>Introduction</b> Robert Prins, PhD – <i>University of California, Los Angeles</i>
5:10 p.m.	<b>The Neural Regulation of Cancer</b> Humsa Venkatesh, PhD – <i>Harvard Medical School</i>
5:30 p.m.	<b>Brain Metastases</b> Daniela Quail, PhD – <i>McGill University</i>
5:50 p.m.	<b>Anti-Tumor Immunity in the Brain (HO, DM) Clinical Trials of Immunotherapy for Glioblastoma</b> Hideo Okada, MD, PhD – <i>University of California, San Francisco</i>
6:10 p.m.	<b>(988) Vagal-CD8+ T Cell Neuroimmune Axis Modulates Liver Cancer</b> Kylynda C. Bauer, PhD – <i>NIH, National Cancer Institute</i>
6:20 p.m.	<b>(956) Glioma-neuronal circuit remodeling induces regional immunosuppression</b> Takahide Nejo, MD, PhD – <i>University of California, San Francisco</i>

## 38<sup>th</sup> Annual Meeting Program Schedule

Saturday, Nov. 4, 2023

### Concurrent Session 208b: Diversity in Patient Populations

**Time:** 5:05–6:30 p.m. PDT

**Location:** Ground Level - Exhibit Hall D - San Diego Convention Center

**Co-Chairs:** Roshan Bastani, PhD – *University of California, Los Angeles*  
Kavita Dhodapkar, MBBS – *Emory University*

5:05 p.m. **Influence of Genetics, Social Stressors on Immunity and Health**  
Roshan Bastani, PhD – *University of California, Los Angeles*  
Kavita Dhodapkar, MBBS – *Emory University*

5:10 p.m. **Bridging the Demographic Divide in Oncology Clinical Trials**  
Sandip Patel, MD – *University of California San Diego Moores Cancer Center*

5:30 p.m. **Aging Tumor Microenvironment**  
Ashani Weeraratna, PhD – *Johns Hopkins University*

5:50 p.m. **Basic Immunology of T Cell Aging**  
Janko Nikolich, MD, PhD – *The University of Arizona College of Medicine*

6:20 p.m. **Panel Discussion**

### Concurrent Session 208c: Manufacturing

**Time:** 5:05–6:30 p.m. PDT

**Location:** Upper Level - Ballroom 6AB - San Diego Convention Center

**Co-Chairs:** Michal Besser, PhD – *Davidoff Center, Rabin Medical Center*  
Isabelle Riviere, PhD – *Takeda*

5:05 p.m. **Introduction**  
Michal Besser, PhD – *Davidoff Center, Rabin Medical Center*  
Isabelle Riviere, PhD – *Takeda*

5:10 p.m. **Conventional Manufacturing (ex vivo expansion) and Next Generation Manufacturing and Automation of T Cells**  
David Stroncek, MD – *GMP Core Facility at NIH*

5:25 p.m. **The Development of Multiplexed-Engineered iPSC-Derived NK cells**  
Bahram Valamehr, PhD – *Fate Therapeutics*

5:40 p.m. **Viral (retro-, lenti-) Manufacturing and Gene Editing Platforms**  
Steven Feldman, MPH, PhD – *Stanford GMP Facility*

5:55 p.m. **Impact of Manufacturing on Function and Efficacy**  
Xiuyan Wang, PhD – *Memorial Sloan Kettering Cancer Center*

6:10 p.m. **Panel Discussion**

### Concurrent Session 208d: Oral Abstract Session

**Time:** 5:05–6:30 p.m. PDT

**Location:** Upper Level - Ballroom 6CD - San Diego Convention Center

**Co-Chairs:** Margaret Callahan, MD, PhD – *Memorial Sloan Kettering Cancer Center*  
Diwakar Davar, PhD – *UPMC Hillman Cancer Center*

5:05 p.m. **Introduction**

## 38<sup>th</sup> Annual Meeting Program Schedule

### Saturday, Nov. 4, 2023

- 5:10 p.m. **(472) Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells**  
Mohamed-Reda Benmebarek, PhD – *National Institutes of Health*
- 5:26 p.m. **(43) Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors**  
Yana Najjar, MD – *UPMC Hillman Cancer Center*
- 5:42 p.m. **(945) Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity and impacts anti-PD-L1 efficacy**  
Santiago Acero Bedoya, MS – *University of Chicago*
- 5:58 p.m. **(892) Non-redundant mechanisms of resistance to immunotherapy and radiotherapy converge on innate immunity**  
Anthony Nguyen, MD, PhD – *Cedars-Sinai Medical Center*
- 6:14 p.m. **(1016) Enforcement of exhausted T cell epigenetic fate by HMG-box transcription factor TOX**  
Yinghui Huang – *University of Pennsylvania*

### Session 209: Awards Ceremony 2

- Time:** 6:30–7 p.m. PDT
- Location:** Ground Level - Exhibit Hall C - San Diego Convention Center
- Chair:** Leisha A. Emens, MD, PhD – *Ankyra Therapeutics*
- 6:30 p.m. **Connect-a-Colleague Top Referrer**  
**JITC Best Paper Awards**  
**JITC Peer Review Mentorship Program Class of 2023 Graduates**  
**Young Investigator Awards**  
**Martin “Mac” Cheever Excellence in Clinical Trial Design - Travel Award**  
**SITC Fellowship Recipients**  
**Sparkathon Class of 2023 Recognition**  
**Presidential Travel Awards**  
**Presidential Award**

### Poster Reception

- Time:** 7–8:30 p.m. PDT
- Location:** Ground Level - Exhibit Hall B - San Diego Convention Center

### The CheckPoints Party

- Time:** 8:30 p.m.–12 a.m. PDT
- Location:** Lobby Level - Grand Ballroom - Marriott Marquis San Diego Marina

## 38<sup>th</sup> Annual Meeting Program Schedule

Sunday, Nov. 5, 2023

### Session 300: NCI Update Session

**Time:** 7:45–8:15 a.m. PST  
**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)  
**Chair:** Marc Ernstoff, MD – *NIH/NCI/DCTD/DTP-IOB*  
**7:45 a.m. Cancer Adoptive Cell Therapy Network**  
Zhang-Zhi Hu, MD – *IOB/DTP/DCTD/NCI*  
**7:55 a.m. Pediatric Immunotherapy Network**  
Anju Singh, PhD – *IOB/DTP/DCTD/NCI*  
**8:05 a.m. Canine Cancer Immunotherapy Network**  
Connie Sommers, PhD – *DTP/DCTD/NCI/NIH*

### Session 301: Organizer Welcome

**Time:** 8:15–8:20 a.m. PST  
**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)  
**Chair:** Harriet Kluger, MD – *Yale University*  
**8:15 a.m. Organizer Welcome**  
Harriet Kluger, MD – *Yale University*

### Session 302: Thomas Waldmann Memorial Plenary Session: Cell-based Immunotherapies for Treatment of Cancer

**Time:** 8:20–10:25 a.m. PST  
**Location:** Ground Level - Exhibit Hall C - San Diego Convention Center  
(Overflow Viewing in Exhibit Hall D)  
**Co-Chairs:** Christine Brown, PhD – *City of Hope*  
Chris Klebanoff, MD – *Memorial Sloan Kettering Cancer Center*  
**8:20 a.m. Introduction**  
Chris Klebanoff, MD – *Memorial Sloan Kettering Cancer Center*  
**8:25 a.m. Genome Editing in T Cells for Cancer Immunotherapy**  
Chiara Bonini, MD – *IRCCS Ospedale San Raffaele, IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele*  
**8:50 a.m. Towards the Develop of Synthetic Immunity to Cancer**  
Kole Roybal, PhD – *University of California, San Francisco*  
**9:15 a.m. Multi-Pronged CAR-T Cell Therapies for Solid Tumors**  
Yvonne Chen, PhD – *University of California, Los Angeles*  
**9:40 a.m. (286) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity**  
Leyuan Ma, PhD – *University of Pennsylvania*  
**9:55 a.m. (768) Transcriptional profiling of Merkel cell carcinoma that escaped polyomavirus-specific TCR-engineered T cells reveals actionable immunotherapy approaches**  
Yuta Asano, PhD – *Fred Hutchinson Cancer Center*  
**10:10 a.m. (247) Memory Reprogramming Enhances CAR T Cell Potency**  
Alexander Doan – *Stanford University School of Medicine*

# 38<sup>th</sup> Annual Meeting Program Schedule

Sunday, Nov. 5, 2023

## Session 303: Hot Topic Symposium: Advances in Gene Editing, Synthetic Biology and Designing Innovative Clinical Interventions

<b>Time:</b>	10:40 a.m.–12:15 p.m. PST
<b>Location:</b>	Ground Level - Exhibit Hall C - San Diego Convention Center (Overflow Viewing in Exhibit Hall D)
<b>Co-Chairs:</b>	Marcella Maus, MD, PhD – <i>Massachusetts General Hospital</i> Kole Roybal, PhD – <i>University of California, San Francisco</i>
10:40 a.m.	<b>Introduction</b> Daniel Chen, MD, PhD – <i>Engenuity Life Sciences</i>
10:50 a.m.	<b>Designing Innovative CAR T Cells for Clinical Use</b> Marcela Maus, MD, PhD – <i>Massachusetts General Hospital</i>
11:15 a.m.	<b>AI-based Presentation: T Cell Specificity, Digital Biology, Machine Learning</b> TBD
11:40 a.m.	<b>In Vivo Modification of Cells – Turning Cell Therapy to Gene Therapy; Therapeutic Window of Cell Therapies in Solid Tumors, Logic-gated Cell Therapy</b> Philip Gregory, PhD – <i>2Seventy Bio</i>
12:05 p.m.	<b>Panel Discussion</b>
12:15 p.m.	<b>Conclusion of SITC's 38<sup>th</sup> Annual Meeting</b>

Schedule is current as of Oct. 16. Visit [www.sitcancer.org/2023](http://www.sitcancer.org/2023) for the most up-to-date schedule.